Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Anne S R, VAN Lindert"'
Autor:
Wouter A. C. van Amsterdam, Joost. J. C. Verhoeff, Netanja I. Harlianto, Gijs A. Bartholomeus, Aahlad Manas Puli, Pim A. de Jong, Tim Leiner, Anne S. R. van Lindert, Marinus J. C. Eijkemans, Rajesh Ranganath
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Randomized Controlled Trials (RCT) are the gold standard for estimating treatment effects but some important situations in cancer care require treatment effect estimates from observational data. We developed “Proxy based individual treatme
Externí odkaz:
https://doaj.org/article/a68451c10dc24dd393e8a5690b3bba25
Autor:
Corine de Jong, Gerarda J. M. Herder, Simone W. A. van Haarlem, Femke S. van der Meer, Anne S. R. van Lindert, Alexandra ten Heuvel, Jan Brouwer, Toine C. G. Egberts, Vera H. M. Deneer
Publikováno v:
Genes, Vol 14, Iss 1, p 170 (2023)
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, disabling side effect in non-small cell lung cancer (NSCLC) patients treated with platinum-based therapy. There is increasing evidence for associations between genetic variant
Externí odkaz:
https://doaj.org/article/2beffaa37dac4e7aacb747e8bb44f21a
Autor:
Mathijs L. Tomassen, Pim J. J. Damen, Helena M. Verkooijen, Max Peters, Janneke van der Stap, Anne S. R. van Lindert, Joost J. C. Verhoeff, Peter S. N. van Rossum
Publikováno v:
Acta Oncologica. 62:237-244
Autor:
Bregje M. Koomen, Mirthe de Boer, Carmen van Dooijeweert, Anne S. R. van Lindert, Ivette A. G. Deckers, Quirinus J. M. Voorham, Stefan M. Willems
Publikováno v:
Virchows Archiv, 707–720. SPRINGER
Programmed death ligand-1 (PD-L1) immunostaining, which aids clinicians in decision-making on immunotherapy for non-small cell lung cancer (NSCLC) patients, is sometimes performed on cytological specimens. In this study, differences in cytology fixat
Autor:
Zulfan Zazuli, Corine de Jong, Wei Xu, Susanne J. H. Vijverberg, Rosalinde Masereeuw, Devalben Patel, Maryam Mirshams, Khaleeq Khan, Dangxiao Cheng, Bayardo Ordonez-Perez, Shaohui Huang, Anna Spreafico, Aaron R. Hansen, David P. Goldstein, John R. de Almeida, Scott V. Bratman, Andrew Hope, Jennifer J. Knox, Rebecca K. S. Wong, Gail E. Darling, Abhijat Kitchlu, Simone W. A. van Haarlem, Femke van der Meer, Anne S. R. van Lindert, Alexandra ten Heuvel, Jan Brouwer, Colin J. D. Ross, Bruce C. Carleton, Toine C. G. Egberts, Gerarda J. M. Herder, Vera H. M. Deneer, Anke H. Maitland-van der Zee, Geoffrey Liu
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 11, p 1233 (2021)
This study aims to evaluate genetic risk factors for cisplatin-induced nephrotoxicity by investigating not previously studied genetic risk variants and further examining previously reported genetic associations. A genome-wide study (GWAS) was conduct
Externí odkaz:
https://doaj.org/article/7373dee5fa83488bb27f8905750962c7
Autor:
Pim J J, Damen, Karijn P M, Suijkerbuijk, Anne S R, VAN Lindert, Wietse S C, Eppinga, Sherif Y, El Sharouni, Joost J C, Verhoeff
Publikováno v:
Anticancer Research. 42:4795-4804
Recent studies described the safety and clinical utility of combined anti-programmed cell death protein-1 (anti-PD1) checkpoint inhibition with radiotherapy. However, long-term follow-up data are lacking. Abscopal effects have been hypothesized, thou
Autor:
Linda M. de Heer, Joost J.C. Verhoeff, W. Hugo van Joolingen, Marnix J.A. Rasing, Max Peters, Mieke J. Aarts, Peter S.N. van Rossum, Anne S R van Lindert
Publikováno v:
Annals of Surgical Oncology. 29:1807-1814
Purpose Irradical resection of non-small-cell lung cancer (NSCLC) is a detrimental prognostic factor. Recently, Rasing et al. presented an internationally validated risk score for pre-treatment prediction of irradical resection. We hypothesized that
Autor:
Quirinus J. M. Voorham, Chantal C H J Epskamp-Kuijpers, Bregje M Koomen, Stefan M. Willems, Carmen van Dooijeweert, Ivette A. G. Deckers, Anne S R van Lindert
Publikováno v:
Lung Cancer, 159, 117-126. ELSEVIER IRELAND LTD
Objectives: Immunohistochemical expression of programmed death-ligand 1 (PD-L1) is used as a predictive biomarker for prescription of immunotherapy to non-small cell lung cancer (NSCLC) patients. Accurate assessment of PD-L1 expression is therefore c
Autor:
Mieke J. Aarts, Mathijs L. Tomassen, Anne S R van Lindert, Joost J.C. Verhoeff, Dirk De Ruysscher, Peter S.N. van Rossum, Max Peters
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 27, Iss, Pp 157-163 (2021)
Clinical and Translational Radiation Oncology, 27, 157-163. Elsevier Ireland Ltd
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, 27, 157-163. Elsevier Ireland Ltd
Clinical and Translational Radiation Oncology
Highlights • Prophylactic cranial irradiation (PCI) use declined in The Netherlands. • Independent predictors for prescription of PCI were identified. • An alarming increase of practice variation was observed. • Alternative MRI surveillance i
Autor:
Mick J. M. van Eijs, Lotte E. van der Wagen, Rogier Mous, Roos J. Leguit, Lisette van de Corput, Anne S. R. van Lindert, Britt B. M. Suelmann, Anna M. Kamphuis, Stefan Nierkens, Karijn P. M. Suijkerbuijk
Publikováno v:
Cancer immunology, immunotherapy : CII.
Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary